Effect of l-carnitine on malnutrition in hemodialysis patients
Phase 2
- Conditions
- Condition 1: Hemodialysis. Condition 2: Malnutrition.Care involving dialysisMalnutritionE40-46
- Registration Number
- IRCT2013042913160N1
- Lead Sponsor
- Yazd Shahid Sadoughi University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
patients on hemodialysis in last year, above 21 years old and did not use the drug for 8 weeks. Did not participate in other research projects.
Exclusion criteria: if a patient is suffering from an infectious disease or fever in last month or is taking antibiotics are excluded
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pre albumin. Timepoint: First, after 3 months at the end of the study. Method of measurement: blood samples,mg/dl.;Transferin. Timepoint: First, after 3 months at the end of the study. Method of measurement: blood samples,mg/dl.;Total lymphocite count. Timepoint: First, after 3 months at the end of the study. Method of measurement: blood samples,mg/dl.;Pre albumin. Timepoint: First, after 3 months at the end of the study. Method of measurement: blood samples,mg/dl.;C-reactive protein. Timepoint: First, after 3 months at the end of the study. Method of measurement: blood samples,mg/dl.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie l-carnitine's impact on visceral proteins in hemodialysis patients?
How does l-carnitine supplementation compare to standard-of-care nutritional interventions for hemodialysis-associated malnutrition?
Which biomarkers correlate with improved nutritional outcomes in hemodialysis patients receiving l-carnitine therapy?
What adverse events are associated with l-carnitine use in hemodialysis patients and how are they managed?
Are there synergistic effects when combining l-carnitine with other anabolic agents like ghrelin or mTOR modulators in treating uremic malnutrition?